Clinical Challenges

Hemolytic Uremic Syndrome

Dawn Camp-Sorrell

squamous cell carcinoma, anemia, thrombocytopenia
ONF 2008, 35(4), 593-596. DOI: 10.1188/08.ONF.593-596

Jump to a section

    References

    Cantrell, J. E., Phillips, T. M., & Schein, P. S. (1985). Carcinoma-associated hemolytic-uremic syndrome: A complication of mitomycin C chemotherapy. Journal of Clinical Oncology, 3(5), 723-734.
    Catalano, C., Gianesini, C., & Fabbian, F. (2002). Erythropoietin is beneficial in mitomycininduced hemolytic-uremic syndrome. Nephron, 91(2), 324-326.
    Coppo, P., Bussel, A., Charrier, S., Adrie, C., Galicier, L., Boulanger, E., et al. (2003). High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine, 82(1), 27-38.
    Gordon, L. I., & Kwaan, H. C. (1999). Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Seminars in Thrombosis and Hemostasis, 25(2), 217-221.
    Korec, S., Schein, P. S., Smith, F. P., Neefe, J. R., Woolley, P. V., Goldberg, R. M., et al. (1986). Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein An immunoperfusion. Journal of Clinical Oncology, 4(2), 210-215.
    Lesesne, J. B., Rothschild, N., Erickson, B., Korec, S., Sisk, R., Keller, J., et al. (1989). Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry. Journal of Clinical Oncology, 7(6), 781-789.
    Muller, S., Schutt, P., Bojko, P., Nowrousian, M. R., Hense, J., Seeber, S., et al. (2005). Hemolytic uremic syndrome following prolonged gemcitabine therapy: A report of four cases from a single institution. Annals of Hematology, 84(9), 621-622.
    Pisoni, R., Ruggenenti, P., & Remuzzi, G. (2001). Drug-induced thrombotic microangiopathy. Drug Safety, 24(7), 491-501.
    Wu, D. C., Liu, J. M., Chen, Y. M., Yang, S., Liu, S. M., Chen, L. T., et al. (1997). Mitomycin-C-induced hemolytic uremic syndrome: A case report and literature review. Japanese Journal of Clinical Oncology, 27(2), 115-118.
    Zakarija, A., & Bennett, C. (2005). Druginduced thrombotic microangiopathy. Seminars in Thrombosis and Hemostasis, 31(5), 681-690.
    Catalano, C., Gianesini, C., & Fabbian, F. (2002). Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome. Nephron, 91(2), 324-326.
    Lesesne, J. B., Rothschild, N., Erickson, B., Korec, S., Sisk, R., Keller, J., et al. (1989). Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry. Journal of Clinical Oncology, 7(6), 781-789.
    Muller, S., Schutt, P., Bojko, P., Nowrousian, M. R., Hense, J., Seeber, S., et al. (2005). Hemolytic uremic syndrome following prolonged gemcitabine therapy: A report of four cases from a single institution. Annals of Hematology, 84(9), 621-622.
    Pisoni, R., Ruggenenti, P., & Remuzzi, G. (2001). Drug-induced thrombotic microangiopathy. Drug Safety, 24(7), 491-501.
    Wu, D. C., Liu, J. M., Chen, Y. M., Yang, S., Liu, S. M., Chen, L. T., et al. (1997). Mitomycin-C induced hemolytic uremic syndrome: A case report and literature review. Japanese Journal of Clinical Oncology, 27(2), 115-118.
    Zakarija, A., & Bennett, C. (2005). Drug-induced thrombotic microangiopathy. Seminars in Thrombosis and Hemostasis, 31(5), 681-690.